Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Chari A, et al. Among authors: sborov dw. Blood Cancer J. 2024 Jul 8;14(1):107. doi: 10.1038/s41408-024-01088-6. Blood Cancer J. 2024. PMID: 38977707 Free PMC article. Clinical Trial.
Performance of newer myeloma staging systems in a contemporary, large patient cohort.
Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov D. Mohyuddin GR, et al. Among authors: sborov d. Blood Cancer J. 2024 Jun 11;14(1):95. doi: 10.1038/s41408-024-01076-w. Blood Cancer J. 2024. PMID: 38862493 Free PMC article. No abstract available.
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Zanwar S, et al. Among authors: sborov d. J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4. J Hematol Oncol. 2024. PMID: 38845015 Free PMC article.
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD Jr, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Khouri J, et al. Among authors: sborov d. Transplant Cell Ther. 2024 Aug;30(8):790.e1-790.e16. doi: 10.1016/j.jtct.2024.05.025. Epub 2024 Jun 2. Transplant Cell Ther. 2024. PMID: 38834151 Free article.
Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias.
Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D. Wagner CB, et al. Among authors: sborov d. Leuk Lymphoma. 2024 Sep;65(9):1362-1365. doi: 10.1080/10428194.2024.2350670. Epub 2024 Jun 2. Leuk Lymphoma. 2024. PMID: 38824620 No abstract available.
100 results